Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
D. Zhou (Guangzhou, China), J. Liao (Guangzhou, China), Y. Chen (Guangzhou, China), J. Wang (Guangzhou, China). Association between Metabolites Biomarkers and Pulmonary Hypertension:A Mendelian Randomization analysis. 1528

Member's Comments

No comment yet.

Related content which might interest you: Mendelian Randomization Study Showed No Causality between Type 2 Diabetes and Pulmonary Hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Clinical Features of Pulmonary Hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Cardiac MRI for Prognosis in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis Source: Virtual Congress 2020 – Imaging-based phenotyping in pulmonary disease Year: 2020 Is there an Optimal Door-to-Treatment Time for Acute Pulmonary Embolism? A National Propensity Match Analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Red Blood Cell Distribution Width as a potential predictor of Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Evaluation of Pulmonary Complication in Patient with Valvular Heart Surgery: Clinical and Laboratory Significances Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems Year: 2018 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Long-Acting Beta Agonist Asthma Pharmacogenetic Loci Identified in Two Multi-Racial Asthma Clinical Trials Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Association between Leflunomide and Pulmonary Hypertension Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021 Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Liquid biopsy for Chronic Thromboembolic Pulmonary Hypertension: Circulating microRNA profile by Next Generation Sequencing Source: International Congress 2017 – PAH and CTEPH Year: 2017 Comprehensive Metabolic Profiling Reveals Metabolic Perturbances and Identifies Potential Biomarkers in Chronic Persistent Bronchial Asthma with Different Levels of Eosinophilia Percentage Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Clinical Risk Stratification of Pulmonary Embolism to Support the Development of a Pulmonary Embolism Response Team (PERT) at a Tertiary Referral Hospital. Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Effect of Pulmonary Rehabilitation on Functional Exercise Capacity and Hypoxemia in Patients with Interstitial Lung Diseases: a retrospective study Source: International Congress 2018 – Aspects of pulmonary rehabilitation and chronic care Year: 2018 Differential Expression of Plasma Metabolites in Patients with Pulmonary Sarcoidosis is Associated with Clinical Behavior Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018 Verification of genetic associations with Scleroderma associated Interstitial Lung Disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019